Immunotherapy has revolutionized the treatment of cancer, enabling durable control of previously incurable and highly aggressive cancers, such as melanoma, in a considerable proportion of patients. Most notably, immune-checkpoint inhibitors that reactivate dysfunctional and/or exhausted T cells have marked efficacy against a broad range of solid and haematological cancers 1, 2 (Supplementary Table S1 ). Moreover, in May 2017, the FDA granted an unprecedented approval to pembrolizumab, an inhibitory antibody that targets the immunecheckpoint receptor programmed cell death protein 1 (PD-1), for the treatment of adult and paediatric patients with unresectable or metastatic, microsatellite instability-high this lack of responsiveness in the majority of patients 2, 4 , nor can the differential expression of immune-checkpoint proteins 1 . Indeed, no robust mechanistic data obtained to date accurately explain the unconventional pattern of clinical response to immune-checkpoint inhibitors 5 . Our hypothesis is that the tumour microenvironment (TME) -characterized by hypoxia, a low pH, and a high interstitial fluid pressure -can reduce the effectiveness of virtually all types of anticancer therapies, including immunotherapy 6 . Thus, normalizing the TME has the potential to improve the effectiveness of immunotherapy 7 . The TME consists of blood and lymphatic vessels, various stromal cells, and resident and infiltrating immune cells, all of which are ensconced in an extracellular matrix. Our work and that of others has revealed that, in comparison with nonmalignant tissues, each component of the TME is abnormal and heterogeneous, and this abnormality fuels tumour progression and treatment resistance 6, 7 . Thus, normalizing components of the TME could improve the outcomes of patients treated with standard and emerging anticancer therapies, including chemotherapeutics, radiation, molecularly targeted agents, and immunotherapeutics 8 . In this Perspective, we focus on one important component of the TME, the tumour vasculature, and discuss how normalizing the tumour vasculature with antiangiogenic agents (BOX 1) could potentially be used to improve the effectiveness of immunotherapy, particularly immune checkpoint blockade (ICB). We also discuss the direct effects of antiangiogenic agents on immune cells, both systemically and in the local TME, and conversely, discuss how immune cells and ICB can alter the tumour vasculature. Given that more than a dozen antiangiogenic drugs that inhibit the VEGF signalling pathway have been approved for the treatment of cancer (Supplementary Table S2 ), and that a number of antiangiogenic agents that target the angiopoietin 1 (ANG1), ANG2, and tyrosine-protein kinase receptor TIE2 (also known as angiopoietin 1 receptor) pathway are in clinical trials, we highlight the potential of these treatments to (MSI-H) or mismatch repair-deficient (dMMR) solid tumours that have progressed after prior treatment, independent of the tissue of origin, provided that no satisfactory alternative treatments are available 3 . This move by the FDA constitutes the first approval of an anticancer drug that is not based on cancer type, or in other words, is 'histology agnostic' . However, 50-80% of patients with tumours for which immune-checkpoint inhibitors are indicated do not benefit from these drugs, and many patients experience severe adverse events (Supplementary Table S1 ). An insufficient abundance of tumour neoantigens -which are a prerequisite for recognition of tumour cells by T cells -alone cannot explain O P I N I O N Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges Dai Fukumura, Jonas Kloepper, Zohreh Amoozgar, Dan G. Duda and Rakesh K. Jain Abstract | Immunotherapy has emerged as a major therapeutic modality in oncology. Currently, however, the majority of patients with cancer do not derive benefit from these treatments. Vascular abnormalities are a hallmark of most solid tumours and facilitate immune evasion. These abnormalities stem from elevated levels of proangiogenic factors, such as VEGF and angiopoietin 2 (ANG2); judicious use of drugs targeting these molecules can improve therapeutic responsiveness, partially owing to normalization of the abnormal tumour vasculature that can, in turn, increase the infiltration of immune effector cells into tumours and convert the intrinsically immunosuppressive tumour microenvironment (TME) to an immunosupportive one. Immunotherapy relies on the accumulation and activity of immune effector cells within the TME, and immune responses and vascular normalization seem to be reciprocally regulated. Thus, combining antiangiogenic therapies and immunotherapies might increase the effectiveness of immunotherapy and diminish the risk of immune-related adverse effects. In this Perspective, we outline the roles of VEGF and ANG2 in tumour immune evasion and progression, and discuss the evidence indicating that antiangiogenic agents can normalize the TME. We also suggest ways that antiangiogenic agents can be combined with immune-checkpoint inhibitors to potentially improve patient outcomes, and highlight avenues of future research.
). Moreover, in May 2017, the FDA granted an unprecedented approval to pembrolizumab, an inhibitory antibody that targets the immunecheckpoint receptor programmed cell death protein 1 (PD-1), for the treatment of adult and paediatric patients with unresectable or metastatic, microsatellite instability-high this lack of responsiveness in the majority of patients 2, 4 , nor can the differential expression of immune-checkpoint proteins 1 . Indeed, no robust mechanistic data obtained to date accurately explain the unconventional pattern of clinical response to immune-checkpoint inhibitors 5 . Our hypothesis is that the tumour microenvironment (TME) -characterized by hypoxia, a low pH, and a high interstitial fluid pressure -can reduce the effectiveness of virtually all types of anticancer therapies, including immunotherapy 6 . Thus, normalizing the TME has the potential to improve the effectiveness of immunotherapy 7 .
The TME consists of blood and lymphatic vessels, various stromal cells, and resident and infiltrating immune cells, all of which are ensconced in an extracellular matrix. Our work and that of others has revealed that, in comparison with nonmalignant tissues, each component of the TME is abnormal and heterogeneous, and this abnormality fuels tumour progression and treatment resistance 6, 7 . Thus, normalizing components of the TME could improve the outcomes of patients treated with standard and emerging anticancer therapies, including chemotherapeutics, radiation, molecularly targeted agents, and immunotherapeutics 8 . In this Perspective, we focus on one important component of the TME, the tumour vasculature, and discuss how normalizing the tumour vasculature with antiangiogenic agents (BOX 1) could potentially be used to improve the effectiveness of immunotherapy, particularly immune checkpoint blockade (ICB). We also discuss the direct effects of antiangiogenic agents on immune cells, both systemically and in the local TME, and conversely, discuss how immune cells and ICB can alter the tumour vasculature. Given that more than a dozen antiangiogenic drugs that inhibit the VEGF signalling pathway have been approved for the treatment of cancer (Supplementary Table S2 ), and that a number of antiangiogenic agents that target the angiopoietin 1 (ANG1), ANG2, and tyrosine-protein kinase receptor TIE2 (also known as angiopoietin 1 receptor) pathway are in clinical trials, we highlight the potential of these treatments to (MSI-H) or mismatch repair-deficient (dMMR) solid tumours that have progressed after prior treatment, independent of the tissue of origin, provided that no satisfactory alternative treatments are available 3 . This move by the FDA constitutes the first approval of an anticancer drug that is not based on cancer type, or in other words, is 'histology agnostic' . However, 50-80% of patients with tumours for which immune-checkpoint inhibitors are indicated do not benefit from these drugs, and many patients experience severe adverse events (Supplementary Table S1 ). An insufficient abundance of tumour neoantigens -which are a prerequisite for recognition of tumour cells by T cells -alone cannot explain improve the outcomes of immunotherapy. We outline opportunities and challenges relating to this emerging strategy to enhance immunotherapy. These concepts and approaches are very timely, considering that patients with cancer will increasingly be treated with various immunotherapies and that biosimilar versions of the anti-VEGF antibody bevacizumab are beginning to be approved (Supplementary Table S3 ).
The abnormal tumour vasculature
The growth and progression of tumours are facilitated by the recruitment of blood vessels. Tumour blood vessels not only supply oxygen and nutrients and remove waste products, but also sustain a favourable niche for so-called cancer stem cells and serve as a conduit for both the metastatic dissemination of tumour cells and the infiltration of immune cells 9, 10 . One would expect a rapidly growing organ or tissue to have normally functioning vessels; however, tumour vessels are abnormal, both structurally and functionally, relative to those of nonmalignant tissues 7 . Perhaps counter-intuitively, this abnormality promotes tumour progression by impairing perfusion, which results in tumour hypoxia and a low pH intratumourally 7 . In addition, the leaky nature of tumour blood vessels, coupled with dysfunctional lymphatic drainage, leads to elevated interstitial fluid pressure in the TME 6 . Tumour cells adapt to overcome these conditions and even to gain a survival advantage over nonmalignant cells through several mechanisms 7 . The abnormal vessels and impaired perfusion can also restrict the entry of cytotoxic drugs and immune cells from the circulation into tumours, limiting activation of the unfolded protein response, a switch to anaerobic metabolism, resistance to autophagy and apoptosis, induction of a cancer stem cell programme, epithelialto-mesenchymal transition, and tumour cell invasion and metastasis 7 . In the following sections, we elaborate on the roles of angiogenic factors in mediating two of these consequences: immunosuppression and metastasis.
Immunosuppression. Anticancer immunity is conferred by both tissue-resident and blood-borne, tumour-infiltrating immune cells. To infiltrate a tumour and integrate into the TME, immune cells must enter the tumour blood vessels, adhere to the endothelium, and transmigrate across the vessel wall 13 . Angiogenic molecules present in the TME, such as VEGF (FIG. 1) , can control the trafficking of immune cells to the tumour by altering the expression of adhesion molecules, including the integrin ligands intercellular adhesion molecule 1 (ICAM1) and vascular cell adhesion protein 1 (VCAM1), on endothelial cells (ECs) and immune cells 10, 14, 15 . Tumour-associated ECs can also express the immune-checkpoint protein programmed cell death 1 ligand 1 (PD-L1), which binds to PD-1 expressed on T cells and thereby suppresses their anticancer activity 16 (FIG. 2) . In addition, tumours secrete soluble factors, such as C-C-motif chemokine ligand 2 (CCL2), CCL28, C-X-C-motif chemokine ligand 8 (CXCL8), CXCL12, ANG2, VEGF, PlGF, and adenosine, all of which promote the recruitment of immuno suppressive cells 7, [17] [18] [19] [20] (FIG. 2) . These cells include immature dendritic cells (DCs), regulatory T (T reg ) cells, myeloid-derived suppressor cells (MDSCs), and tumour-associated macrophages (TAMs) with pro-tumour phenotypes. In turn, through the production of various cytokines and growth factors, such as VEGF, ANG2, IL-10, and transforming growth factor β (TGFβ), these leukocytes work in concert with tumour cells and ECs lining abnormal tumour blood vessels to promote angiogenesis and both local and systemic immunosuppression 7 (FIGS 1-3).
Among various angiogenic molecules, VEGF is known to have diverse activities in the TME
. In particular, the roles of VEGF in systemic and local immunosuppression have been extensively investigated in tumour models 7, 15, 21 . Excessive levels of VEGF in the TME induce tumour-associated immunosuppression via at least four distinct mechanisms (FIG. 1; their anticancer activity. Furthermore, the abnormal TME might modulate the activity and, thus, the effectiveness of these drugs and immune cells after they accrue in the tumour. For example, an adequate level of oxygen is required for many drugs and immune cells to kill cancer cells 7 . Additionally, various cytokines produced by diverse cell types in response to hypoxia and the low pH in the TME can cause both local (FIGS 1, 2) and -after entering the circulation -systemic immunosuppression (FIG. 3) . Finally, the abnormal blood and lymphatic vessels also facilitate tumour invasion and metastasis via multiple mechanisms 6 . For example, fluid leaking out of a tumour, owing to insufficient drainage via the defective intratumoural lymphatic system, can carry cancer cells to nearby peri-tumour lymphatic vessels, thereby promoting lymphatic metastasis 11 . Abnormal leaky vessels might also facilitate intravasation and shedding of cancer cells into the blood; after entering the systemic circulation, some of these tumour cells can disseminate to distal organs and form metastases. Moreover, the cytokines, such as VEGF, that seep from the TME into the systemic circulation can also potentiate the extravasation of metastatic cancer cells out of the blood vessels within distant organs 12 . By contrast, while CD8 + cytotoxic T lymphocytes (CTLs) can also home to tumours, multiple factors present in the TME often render these cells dysfunctional and/or limit their penetration into the tumour (FIGS 1,2) . Other adverse consequences of abnormal tumour vasculature and the resulting conditions in the TME include inflammation, fibrosis, genomic instability, DNA hypermethylation,
Box 1 | From tumour starvation to vessel normalization
The discovery that VEGF is a key mediator of angiogenesis prompted concerted efforts to target this pathway therapeutically, with the goal of inducing regression of blood vessels to starve tumours of oxygen, glucose, and other essential metabolites. Proof of principle for anti-VEGF therapy was demonstrated in preclinical tumour models, leading to rapid clinical translation of this approach and the development of many drugs targeting the VEGF pathway -with the anti-VEGF antibody bevacizumab being the most widely prescribed antiangiogenic drug 7 (Supplementary  Table S2 ). Bevacizumab alone does not confer a clinically or statistically significant overall survival benefit to patients with metastatic colorectal cancer or glioblastoma; however, the combination of bevacizumab or other VEGF pathway inhibitors with cytotoxic therapies has been demonstrated to result in clinically meaningful overall survival benefits for patients with advanced-stage colorectal cancer, non-small-cell lung cancer, mesothelioma, or cervical cancer, but not those with other cancers, such as breast cancer, prostate cancer, or glioblastoma [127] [128] [129] [130] [131] [132] [133] [134] (Supplementary  Table S2 ). These results prompted fundamental mechanistic studies to elucidate how antiangiogenic therapies targeting VEGF and other angiogenic factors, initially developed to reduce the delivery of metabolites to tumours, somewhat paradoxically improve the effectiveness of systemic chemotherapy. In 2001, we proposed the vessel normalization hypothesis as an explanation to resolve this conundrum 61 , and this concept has been validated in a number of preclinical and clinical studies 7 . Supplementary Table S4 ). First, increased VEGF directly inhibits CTL trafficking, proliferation, and effector function 22 . Second, VEGF inhibits DC maturation and antigen presentation, thus hampering T cell activation and, consequently, diminishing the T cell-mediated anticancer immune response 23, 24 . Third, high levels of VEGF promote the recruitment and proliferation of immunosuppressive cells, including T reg cells, MDSCs, and pro-tumour, M2-like TAMs 25, 26 . Fourth, VEGF promotes angiogenesis that results in an aberrant tumour vasculature, leading to hypoxia and a low pH in the TME, which in turn fosters immunosuppression both locally (FIG. 2) and systemically (FIG. 3) , as discussed above 21, 27, 28 . In contrast to VEGF, the immunomodulatory roles of ANG2, which is another key regulator of angiogenesis
, are not well understood. Nevertheless, in experimental models, activated ANG2 signalling has been shown to promote immunosuppression in tumours through multiple mechanisms (Supplementary  Table S4 ). First, ANG2 increases leukocyteendothelial interactions via upregulation of adhesion molecules, thereby facilitating the recruitment of MDSCs 29 , T reg cells 30 , and TIE2-expressing monocytes that induce immunosuppression 31 . Second, ANG2 disrupts EC-pericyte contacts, thus facilitating the migration of immune cells out of the vasculature and into the TME 32, 33 . Finally, ANG2 also modulates the function of monocytes by suppressing the secretion of tumour necrosis factor (TNF), thus restricting their anticancer activity 34 . Experimental data indicate that VEGF and ANG2 might cooperate to induce tumour immunosuppression and that this effect might be dependent on the relative levels of these cytokines in the TME [35] [36] [37] . Importantly, however, preclinical evidence indicates that high-dose and/or long-term antiangiogenic therapy causes massive vessel pruning and increases immuno suppression in tumour models [37] [38] [39] [40] , suggesting that an optimum level of VEGF and ANG2 blockade will be needed to alleviate immunosuppression in the TME. Interestingly, emerging data suggest that immunosuppression, in turn, contributes to resistance to antiangiogenesis treatments [37] [38] [39] 41 .
Metastasis.
As outlined above, overexpression of angiogenic factors in the TME might facilitate the metastatic process by causing structural and biochemical abnormality of tumour blood and lymphatic vessels. In fact, targeting of an antibody targeting VEGF receptor 2 (VEGFR2) increased the efficacy of HER2-targeted therapies against established brain metastases from HER2-positive breast cancer in a mouse xenograft model 43 .
In animal models, VEGF also exerts pro-metastatic effects through activation of the calcineurin-nuclear factor of activated VEGF with bevacizumab has been shown to reduce the incidence of brain metastasis in a mouse model of non-small-cell lung cancer (NSCLC), and when combined with carboplatin and paclitaxel, is associated with a reduced frequency of brain metastases as a site of first relapse in patients with this disease 42 . Similarly, treatment with Nature Reviews | Clinical Oncology . This finding was further confirmed in a different study 89 . While VEGF directly inhibits the development and/or activation of cytotoxic T lymphocytes (CTLs), CTL-produced VEGF can induce angiogenesis and promote tumour progression 97 . Furthermore, VEGF has been shown to increase the numbers of CD4 + memory T cells (Supplementary Table S4 ). VEGF can promote the expansion of myeloid-derived suppressor cells (MDSCs) and improve their immunosuppressive function in the tumour microenvironment (TME) 23 . Importantly, dendritic cells (DCs), which are required for priming of CTLs, lose their ability to mature and present antigens following VEGF exposure in vitro. Consequently, the anticancer activity of CTLs in the TME might be compromised. In this context, CTLs have a decreased capacity to traffic to the tumour, proliferate, and produce cytokines that are integral to the anticancer immune response, such as IFNγ and tumour necrosis factor 172 . Collectively, T reg cells, TAMs, MDSCs, and immature DCs suppress the activity of CTLs, resulting in a pro-tumour microenvironment. The roles of ANG2 (and ANG1) in modulating various immune cells are not as well understood as those of VEGF; thus, the effects of ANG2 are not illustrated in this figure. T cells (NFAT) pathway via upregulation of ANG2 expression in ECs 44 . In line with these preclinical data, high levels of ANG2 expression determined by transcriptomic analysis of tumour samples correlate with an increased metastatic burden in patients with breast cancer 45 . Mechanistically, ANG2 might facilitate the metastatic process indirectly by disrupting pericyte attachment to the endothelial wall, structurally and functionally compromising the vasculature, and thereby causing hypoxia 46 . Hypoxia in the TME leads to cytoskeletal changes in tumour cells that are essential for migration cell dissemination to tumour-draining lymph nodes and distant tissues 47, 48 , and has therapeutic inhibitory effects on the growth of established metastatic lesions 47 . Similarly, inhibition of vascular endothelial protein tyrosine phosphatase (VEPTP; also known as PTPRβ), which sustains endogenous activation of TIE2, also inhibited extravasation of metastatic breast cancer cells into the lungs and subsequent metastatic foci formation, and thus extended survival durations, in animal models of mammary cancer when added to adjuvant doxorubicin chemotherapy 49 . These findings are in line with those of studies in which a high level of ANG2 pathway activation led to lymph node invasion and metastasis in breast cancer models (Supplementary Table S5 ), and of studies showing that high levels of ANG2 expression in patients with breast cancer correlate with the presence of metastatic disease [50] [51] [52] . The key role of VEGF and ANG2 in promoting metastasis is further illustrated by studies using models of resistance to anti-VEGF therapy. In this setting, ANG2 promoted the upregulation of endothelial CCL2 and ICAM1 expression in metastases and, in turn, promoted the recruitment and adhesion of tumour-promoting TIE2 -CCR2 + macrophages 53 . Dual VEGF-ANG2 inhibition was also more efficacious in breast cancer models than anti-VEGF therapy alone, with a reduce frequency of metastatic dissemination and thus decreased formation of micrometastatic nodules 54 . Of note, while anti-VEGF therapy in combination with chemotherapy has been associated with improved patient survival in the metastatic setting across a number of solid tumour types, such treatment was found to be inefficacious in all phase III trials performed in the adjuvant setting to date 6 . This disparity is, in part, attributed to VEGFindependent nonangiogenic mechanisms of vascularization (such as vessel co-option) that are exploited by cancer cells at the early stages of metastasis formation 6, 9, 55, 56 . By contrast, ICB has shown promise in the adjuvant setting in patients with melanoma or NSCLC [57] [58] [59] . Thus, a better understanding of the interactions between VEGF and ANG2 signalling might offer novel strategies to prevent and treat metastasis and increase the effectiveness of other therapeutic approaches such as immunotherapy, including ICB.
Strategies to normalize tumour vessels Multiple molecular and physical mechanisms contribute to vascular dysfunction in tumours 7, 60 ; chief among and invasion and thus the metastatic process. The lack of pericyte fortification might also facilitate intravasation of tumour cells into blood and lymphatic vessels. Indeed, transgenic mice with EC-specific overexpression of ANG2 have decreased endothelial integrity, resulting in increased metastatic foci formation in the Lewis lung carcinoma model 32 . Interestingly, metastatic dissemination could be prevented by treatment of the mice with an ANG2-neutralizing antibody 32 . In other mouse tumour models, anti-ANG2 therapy has been shown to prevent metastasis through the inhibition of tumour Abnormalities in the tumour vasculature result in hypoxia and acidosis of the tumour microenvironment (TME), which in turn contribute to immunosuppression via several mechanisms. These mechanisms include increased accumulation, activation, and expansion of immunosuppressive regulatory T (T reg ) cells; recruitment of inflammatory monocytes and tumour-associated macrophages (TAMs) and reprogramming of TAMs from an anticancer M1-like phenotype towards the pro-tumour M2 phenotype; suppression of dendritic cell (DC) maturation, which results in impaired antigen presentation and activation of tumour-specific cytotoxic T lymphocytes (CTLs); and expansion of abnormal endothelial cells (ECs) with immunosuppressive phenotypes. Importantly, the programmed cell death protein 1 (PD-1)-programmed cell death 1 ligand 1 (PD-L1) pathway is often activated in the TME as a mechanism to evade anticancer immune responses, with upregulation of PD-L1 expression on TAMs, DCs, and ECs, as well as on tumour cells. In addition, tumour-infiltrating CTLs typically upregulate PD-1, marking them as dysfunctional or 'exhausted' and limiting their cytotoxic potential against tumour cells. Overall, the consequence of aberrant tumour angiogenesis and vascular abnormality is an immunosuppressive TME. ANG2, angiopoietin 2; CCL, C-C-motif chemokine ligand; CXCL12, C-X-C-motif chemokine ligand 12; CSF1, macrophage colony-stimulating factor 1; FASL, FAS antigen ligand; GM-CSF, granulocyte-macrophage colony-stimulating factor; TGFβ, transforming growth factor β.
them is the imbalance of signalling mediated by proangiogenic versus antiangiogenic molecules 28 . In nonmalignant tissues, this balance is exquisitely maintained to ensure the normal morphology and function of blood vessels. During carcinogenesis, however, this balance typically tips towards angiogenesis, and the vessels become chronically immature and abnormal. In 2001, we proposed to restore this balance using judicious doses of antiangiogenic agents and suggested that this strategy would transiently give rise to tumour vessels with structural and functional phenotypes closer to those of the vessels of nonmalignant tissues -a state we referred to as 'normalized' (REF. 61 ), because the vessels would not be perfectly normal
. We also suggested that the use of other therapies during this 'window of normalization' (REF. 61 ) would result in better outcomes than if the same agents were given before or after this window.
We initially tested our vascular normalization hypothesis in mice using agents that target the central regulator of angiogenesis: VEGF
. Our work provided compelling evidence in support of this hypothesis. For example, radiation therapy given during the window of normalization, especially when hypoxia was alleviated in tumours, had outcomes superior to those achieved when radiation was delivered outside this window 62 . A number of preclinical and clinical studies from our own institution and others have also provided evidence in support of the validity of this hypothesis for a number of malignancies 16, 63 . Our initial efforts focused on cytotoxic therapies 64 , but we subsequently showed in preclinical studies that vascularnormalizing doses of anti-VEGF agents also convert the immunosuppressive TME normalization has been observed 62 ; the window of normalization might be of short duration (days to weeks) and is dependent on the tumour and dose of anti-VEGF agent used 27 . In our attempts to extend the normalization window in experimental models of cancer, we discovered that ANG1/ANG2-TIE2 signalling (BOX 3) mediates the recruitment of pericytes to the tumour vessels 62 , and that ectopic expression of ANG2 can abrogate the benefit of anti-VEGF therapy 66 . Moreover, concomitant blockade of ANG2 and VEGF extends both the window of normalization and the survival benefit compared with inhibition of either pathway alone, in part, by reprogramming the immuno suppressive TME 35, 36 . Interestingly, in patients with glioblastoma, circulating ANG2 levels rebound after a marked initial decrease following treatment with a VEGF pathway inhibitor 67 . Perhaps most pertinent to immunotherapy, ANG2 levels have been reported to be elevated or increased in patients with melanoma who have an unfavourable response to ICB 68 . Importantly, ANG2 levels were predictive of treatment response to ICB with or without anti-VEGF therapy 68 . A number of lessons can be learnt from the findings of these and other preclinical and clinical studies reported to date.
The dose of anti-VEGF agents matters.
Preclinical data indicate that anti-VEGF therapy results in vascular normalization via pruning of immature blood vessels, which have poor pericyte coverage, and via active pericyte recruitment 62, 69 . Similar vascular changes have also been observed using advanced MRI techniques in patients to an immunosupportive one and improve the outcome of vaccine-based anticancer immunotherapy 27 . The findings of multiple other groups provide further evidence of these effects in preclinical models using different anti-VEGF agents, as well as different immunotherapies 7, 13 (TABLE 1) , and such combinations are currently being tested in a number of clinical trials (TABLE 2) . In fact, the results of a phase II trial demonstrate the benefit of such an approach for patients with advanced-stage renal cell carcinoma (RCC)
, and the results of a follow-up phase III trial comparing anti-PD-1 therapy plus axitinib with standard sunitinib monotherapy in the first-line treatment of metastatic RCC are forthcoming (TABLE 2) . While RCC is a highly VEGF-dependent tumour, these early results point to the multiple roles of VEGF pathway inhibition in anticancer immunity.
A major challenge with anti-VEGF therapies is that only transient vascular
Box 2 | The diverse functions of VEGF signalling in the tumour microenvironment
The VEGF family of growth factors includes VEGFA, VEGFB, VEGFC, VEGFD, and PlGF 135 . VEGFA (referred to as VEGF) signals mainly through VEGF receptor 2 (VEGFR2; also known as KDR) 9 . VEGF, which was initially identified as a vascular permeability factor 136 , was cloned in 1989 and subsequently established as a crucial survival factor and mitogen for endothelial cells (ECs) 137 , and as the central regulator of angiogenesis in physiological and pathological contexts 136, 138, 139 . Both cancer cells and stromal cells in the tumour microenvironment (TME) can produce VEGF 140 . ECs and tumour cells respond to autocrine and paracrine VEGF signalling 141 , and other cell types present in the TME, such as immune cells, can also express VEGFRs 9,142-147 (Supplementary  Table S4 ). Indeed, VEGF not only modulates the expression of adhesion molecules on ECs, thereby regulating leukocyte recruitment, but also functions as a chemokine for subsets of immune cells and thus guides their recruitment to, and regulates their activity in, the TME. In general, VEGF signalling has been implicated in fostering immunosuppression, both systemically and in the local TME 15 (FIGS 1,2,3; Supplementary Table S4) . Thus, VEGF signalling has diverse functions, all of which might influence the biological and clinical outcomes of antiangiogenic therapies, and should therefore be considered in efforts to optimize the use of such agents. 63, 67 . The onset of vessel normalization conferred by anti-VEGF treatment can occur in as little as 1 day in both mouse 62 and human tumours 67 . The normalization process is transient and reversible, in a tumour-dependent and dose-dependent manner, and lasts for around 1 week in mice and possibly for a few months in humans 7, 62, 63, 67 . The window of vessel normalization ends when an excessive number of vessels are pruned, or when tumours switch to the use of alternative angiogenic pathways or alternative mechanisms of blood vessel recruitment, such as vessel co-option 56, 62 . Notably, high doses of antiangiogenic agents can result in a short normalization window by causing excessive amounts of vessel pruning, thus exacerbating hypoxia and acidosis in the TME 7 . High doses of anti-VEGF agents can also lead to increased deposition of extracellular matrix that, together with hypoxia, can promote the infiltration of immunosuppressive and/or pro-tumour immune cells, such as monocytic and granulocytic MDSCs [37] [38] [39] . These results suggest that high-dose anti-VEGF therapy limits the benefits of chemotherapy in mouse models and in patients with metastatic colorectal cancer (CRC) or advanced-stage NSCLC 37, 70, 71 . Similarly, blockade of VEGF signalling using high doses of the multi-target, pan-VEGFR TKI sorafenib caused increased hypoxia and the stromal cell-derived factor 1 (SDF1)-mediated recruitment of immunosuppressive cells, such as T reg cells and M2-like macrophages, in a mouse model of advanced-stage hepatocellular carcinoma (HCC); blockade of the SDF1 receptor C-X-C-chemokine receptor 4 (CXCR4) prevented this shift towards an immunosuppressive TME, full potential of antiangiogenic therapy, the dose and schedule of anti-VEGF agents might need to be tailored to baseline levels of tumour vascularity 78 and/or VEGF. Notably, pre-treatment levels of circulating VEGF are prognostic for treatment outcome in different solid tumour settings, but are not predictive of anti-VEGF therapy outcome 79 . Whether pre-treatment VEGF levels are predictive in the context of personalized bevacizumab dosing regimens is unknown. This hypothesis needs to be tested in prospective studies using low-dose antiangiogenic therapy.
ANG2 might confer resistance to anti-VEGF therapy. Similar to other anticancer drugs (such as molecularly targeted agents), tumours inevitably develop resistance to anti-VEGF agents, and one key mediator of resistance is the hypoxia induced by exposure to these drugs 7 . Several cellular and molecular mechanisms of escape from antiangiogenic therapies have been postulated and investigated, including activation of alternative angiogenic pathways, recruitment of proangiogenic myeloid cells, increased pericyte cell coverage of tumour blood vessels, increased tumour cell invasion, and alternative modes of vessel recruitment 7, 9, 80 . Herein, we focus on activation of the ANG2-TIE2 axis as an escape mechanism from anti-VEGF treatment for the following reasons. First, ANG1 mediates vascular normalization in preclinical models 62 , whereas overexpression of ANG2 can compromise the benefit of VEGF pathway inhibition by abrogating vessel normalization 66 . Second, ANG2 is co-expressed with VEGF in many human solid tumours, such as glioblastoma 35 , HCC 81 , and CRC 82 . Third, circulating levels of ANG2 transiently decrease during the window of normalization and return back to baseline levels as the tumours progress after anti-VEGF therapy in patients with glioblastoma 67 . Fourth, tumour-derived VEGF can increase the expression of ANG2 in ECs, which results in activation of the endothelium and thus promotes lung metastasis in mouse models, suggesting that an interaction between these angiogenic pathways promotes tumour progression 44 . Finally, ANG2 is a candidate predictive and/or prognostic marker of therapeutic responsiveness to anticancer treatments, including immunotherapy using immune-checkpoint inhibitors, as discussed below (BOX 4; Supplementary Table S6) .
inhibited tumour growth and metastasis, and improved the survival of sorafenibtreated mice 40 . In mouse models of CRC, high-dose anti-VEGF treatment can also result in the recruitment of immunosuppressive, nonclassical, lymphocyte antigen 6C (Ly6C) low monocytes that also confer resistance to anti-VEGF therapy, thus setting up a vicious cycle 38, 39 . By contrast, use of lower doses of antiangiogenic agents -for instance, as low as one-quarter of the doses that induce antivascular effects and/or vessel pruning in animal studies -has the potential to induce prolonged vessel normalization 7, 27 . Achieving vascular normalization, and thereby reducing tumour hypoxia and acidosis, is crucial because these stressors confer cancer cells with an invasive metastatic phenotype 72 . Moreover, a normalized vasculature provides a conduit for the efficient infiltration of immune cells and delivery of anticancer therapeutics into tumours 6, 27 . Importantly, restoring tumour oxygenation and a physiological pH might improve the anticancer activity of infiltrating immune cells 27 , as well as that of radiation therapy and many drugs 7 (FIGS 2,4). Treatment-resistant cancer stem cells are hypothesized to reside in the hypoxic niche, and excessive antiangiogenic therapy can cause hypoxia and thereby support these cells 73 . Therefore, low doses of antiangiogenic agents might also reduce the number of these stem cells, hence avoiding or delaying therapy resistance. In fact, the results of two retrospective studies have shown that low-dose bevacizumab (<3.6 mg/kg per week) in combination with chemoradiotherapy confers a greater survival benefit than high-dose bevacizumab (5 mg/kg per week) in patients with glioblastoma [74] [75] [76] [77] . Hence, to realize the Box 3 | The angiopoietin-TIE2 pathway Angiopoietin 1 (ANG1) and ANG2 are key angiogenic cytokines that signal through the ANG1 and ANG2 receptor (TIE2), which is expressed primarily on vascular endothelial cells (ECs). ANG1 is expressed by pericytes 148 and maintains the stability of quiescent mature vessels through its agonistic effects on TIE2 by promoting cell-cell adhesion between ECs 149, 150 , desensitizing ECs to apoptotic signals [151] [152] [153] , maintaining pericyte-EC contacts 154 , and downregulating ANG2 expression by ECs 150 . The crucial role of pericyte-derived ANG1 is underlined by the fact that this cytokine, when overexpressed in transgenic mouse models, could restore the functional integrity of leaky blood vessels that were induced by transgenic overexpression of VEGF in non-tumour-bearing mice 155 . ANG2 is released by ECs upon their activation 156 , in the course of inflammation 157 and in response to hypoxia 158 . However, tumour cells can be an alternative source of ANG2 (REFS 159-161 ). ANG2 can be either an agonistic or an antagonistic ligand of TIE2 in a context-dependent manner: in mice, the antagonistic effects of ANG2 on TIE2 can destabilize quiescent vessels 162 , enabling VEGF-induced angiogenesis to occur 163 , although ANG2 has also been shown to act as a partial TIE2 agonist in mouse tumour models 164 . Finally, ANG2 has also been implicated as a crucial regulator of the development and quiescence of lymphatic vessels 162 . 
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These results were compiled on the basis of a systematic search of the PubMed database using selected search terms from the abbreviations list. ↑ indicates increased cell numbers or an improvement in outcome compared with those observed with control treatments. ↓ indicates decreased cell numbers or a decrease in the outcome measured compared with control treatments. ANG2, angiopoietin 2; CEA, carcinoembryonic antigen; DC, dendritic cell; GM-CSF, granulocytemacrophage colony-stimulating factor; HEVs, high endothelial venules; IgG, immunoglobulin G; LTβR, lymphotoxin-β receptor; mAb, monoclonal antibody; MDSCs, myeloid-derived suppressor cells; NA, not applicable; PD-1, programmed cell death protein 1; PD-L1, programmed cell death 1 ligand 1; sVEGFR, soluble VEGF receptor; TKI, tyrosine kinase inhibitor; T reg , regulatory T; VEGFR, VEGF receptor. 
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Blocking both ANG1 and ANG2 might not be of benefit to patients. Therapeutic agents that target the ANG2-TIE2 axis can lead to tumour regression in a number of subcutaneous and orthotopic mouse models (Supplementary Table S7 ); many of these agents have been advanced to testing in clinical trials (Supplementary Table S8) . Notably, however, the results of clinical studies targeting both ANG1 and ANG2 using the bi-specific peptibody trebananib have been disappointing. In a phase II trial involving patients with CRC , as well as the results of the aforementioned phase II studies of this agent [83] [84] [85] , suggests that the vessel-normalizing effects of ANG1-ANG2 blockade are generally insufficient to improve patient outcomes. One possible reason for the clinical failure of dual trebananib to cisplatin and capecitabine chemotherapy failed to prolong the estimated median PFS duration in patients with metastatic gastroesophageal cancer (HR 0.98, 95% CI 0.67-1.43; P = 0.92) in a randomized, double-blind, placebo-controlled phase II study 84 . In a different phase II trial 85 , trebananib in combination with sorafenib failed to improve the PFS of patients with metastatic clear cell RCC when compared with sorafenib plus placebo (HR 0.88, 95% CI 0.60-1.30; P = 0.52). Interestingly, in the phase III TRINOVA-1 trial of trebananib plus paclitaxel in women with recurrent ovarian cancer 86 , only patients with ascites at baseline had a statistically significant improvement in overall survival (14.5 months versus 12.3 months with paclitaxel plus placebo; HR 0.72, 95% CI 0.55-0.93; P = 0.011). PFS was also significantly improved in the overall NA (189) These results were compiled on the basis of a systematic search of the PubMed database using selected search terms from the abbreviations list. AEs, adverse events; ANG2, angiopoietin 2; CAR, chimeric antigen receptor; CDCA1, hypothetical protein LOC100191040; CRC, colorectal cancer; CRP, C-reactive protein; CTL, cytotoxic T lymphocyte; CTLA-4, cytotoxic T lymphocyte protein 4; DC, dendritic cell; DLTs, dose-limiting toxicities; GM-CSF, granulocyte-macrophage colony-stimulating factor; HCC, hepatocellular carcinoma; mAb, monoclonal antibody; MDSCs, myeloid-derived suppressor cells; MET, hepatocyte growth factor receptor; MTD, maximum tolerated dose; NA, not applicable; NK, natural killer; NSCLC, non-small-cell lung cancer; ORR, objective response rate; OS, overall survival; PD-1, programmed cell death protein 1; PD-L1, programmed cell death 1 ligand 1; PECAM1, platelet endothelial cell adhesion molecule; PFS, progression-free survival; PR, partial response; RCC, renal cell carcinoma; RFS, relapse-free survival; RP2D, recommended phase II dose; SD, stable disease; sVEGFR, soluble VEGF receptor; TKI, tyrosine kinase inhibitor; TNFRSF4, tumour necrosis factor receptor superfamily member 4 (also known as OX40); T reg , regulatory T; TTK, dual-specificity protein kinase; URLC10, upregulated in lung cancer 10; VEGFR, VEGF receptor.
ANG1-ANG2 blockade is that inhibition of ANG1, which is an agonistic ligand of TIE2 Table S8 ).
Targeting both VEGF and ANG2 might increase vascular normalization and promote anticancer immunity. The complementary roles of VEGF and ANG2 in tumour angiogenesis have motivated a plethora of preclinical studies attempting to investigate concurrent blockade of both receptors for these cytokines in multiple tumour models (Supplementary Table S9 ). This dual blockade approach can provide tumour control in some preclinical models, although the degree of benefit and the underlying mechanism of action seem to be context-dependent 31, 32, 80, 89 . For example, is dependent on the tumour type (or model used), the stage of disease progression, and the specific characteristics of the TME. With regard to the nature of the TME, the therapeutic benefits of dual VEGF-ANG2 blockade seem to be conferred through the lymphoid (for example, in breast and colon tumour models 16 ) and/or myeloid cell populations (in both central nervous system (CNS) and non-CNS tumour models 16, 35, 36, 90 ). In the lymphoid compartment, the extravasation and perivascular accumulation of both CD4 + and CD8 + T cells increased in response to treatment with an anti-VEGF-ANG2 bispecific antibody (A2V) in genetically engineered and xenograft mouse models of metastatic breast cancer, PNETs, or melanoma 16 . As expected, T cell accumulation was confined to tumour areas with normalized vessels 16 . The overall number of T cells in the tumour mass, however, was unchanged 16, 35, 36 . Nevertheless, the anticancer activity -an important determinant of durable tumour control -of the T cells was improved, with increased production of IFNγ and increased expression of the activation marker CD69 on CTLs with this treatment compared with the results of monotherapy with neutralizing antibodies to either ANG2 or VEGF alone 16 . In the myeloid compartment, reprogramming of pro-tumour, M2-like TAMs towards an anticancer M1 phenotype has been shown to be a major contributor to the therapeutic efficacy of dual antiangiogenic therapy targeting VEGF and ANG2, independent of the tumour model used 16, 35, 36 . Reprogramming of TAMs to an anticancer phenotype might be critical in patients with glioblastoma, in which macrophages constitute up to 40% of the tumour mass 91 . In preclinical glioblastoma models, macrophage depletion with an antibody against macrophage colonystimulating factor 1 (CSF1) abrogated the benefits of dual VEGF-ANG2 inhibition, thus demonstrating the importance of TAMs in mediating the treatment effects 36 . Of note, CSF1 pathway inhibition is currently being pursued in clinical trials (NCT02526017, NCT02777710, and NCT02471716); caution should be taken if these agents should ever be combined with dual VEGF-ANG2 inhibition.
Currently, multiple clinical trials are being conducted to investigate dual inhibition of VEGF and ANG2 in patients with cancer (Supplementary Table S10) . We anticipate that an extended window of vessel normalization and reprogramming dual VEGF-ANG2 blockade prolonged survival compared with anti-VEGF or anti-ANG2 monotherapy in mouse models of glioblastoma 35, 36 , melanoma 16 , pancreatic neuroendocrine tumours (PNETs) 16 , and metastatic 16, 90 or early stage (resected) breast cancer 90 . By contrast, a survival benefit was not observed in a model of metastatic RCC (RENCA) with VEGF-ANG2-neutralizing therapy 90 . Treatment with the pan-VEGFR TKI sunitinib in combination with an ANG2-neutralizing antibody, however, led to a decreased frequency of lung metastases from orthotopic RENCA tumours, possibly owing to inhibitory effects on multiple kinases with diverse activities 90 . Dual VEGF-ANG2 inhibition has also been shown to be more efficacious than anti-VEGF monotherapy in breast cancer models, as indicated by reduced metastatic dissemination and micrometastatic growth 54 . Taken together, these findings suggest that the benefit of dual antiangiogenic therapy The structural and functional abnormalities of tumour blood vessels lead to impaired blood flow and perfusion, thus resulting in a hypoxic tumour microenvironment (TME). Hypoxic conditions in tumours limit the effectiveness of cytotoxic therapies, such as radiation therapy and certain chemotherapies. In addition, drug delivery to the tumour via these abnormal vessels is impaired, and this problem is further exacerbated by the high interstitial fluid pressure -a consequence of the leaky blood vessels and irregular lymphatic system in the tumour. Moreover, abnormal and leaky tumour blood vessels facilitate the intravasation of cancer cells into the systemic circulation, promoting metastasis. Furthermore, the abnormal TME is associated with increased infiltration of immunosuppressive regulatory T cells and polarizes tumour-associated macrophages from an anticancer M1-like phenotype towards an immunosuppressive M2 phenotype. The dysfunctional vasculature also restricts the accumulation and homogeneous intratumoural distribution of effector T cells. Consequently, anticancer immune responses are severely impaired. Vascular normalization could potentially prevent or reverse many of these adverse effects in patients, enhance the delivery and effectiveness of chemotherapy and immunotherapy, and improve the anticancer effects of radiotherapy. of the TME towards an immuno stimulatory phenotype will be achieved using this approach compared with standard-dose anti-VEGF therapy. We speculate that the effects of dual VEGF-ANG2 targeting could even be further improved through the judicious use of low doses of anti-VEGF agents 75, 92, 93 . Notably, a knowledge gap exists with respect to the dosing and scheduling (for example, simultaneous or sequential) of agents for dual targeting of VEGF and ANG2; careful dose selection for dual antiangiogenic treatments in clinical trials will be crucial for avoiding excessive pruning of vessels and for increasing the delivery of drugs to the tumour.
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On the basis of evidence from multiple preclinical studies 16, 35, 36 , we anticipate that dual VEGF-ANG2 blockade alone will not enable durable clinical responses similar to those conferred in some patients by immune-checkpoint inhibitors. For example, in the phase II McCAVE study involving patients with untreated metastatic CRC (NCT02141295), addition of the bispecific anti-VEGF-ANG2 antibody vanucizumab to 5-fluorouracil, folinic acid, and oxaliplatin (FOLFOX) chemotherapy was not sufficient to prolong PFS (the primary end point of the trial) compared with FOLFOX plus bevacizumab. The failure to meet the primary end point of this clinical trial might be explained by the high doses of vanucizumab used (2,000 mg every 2 weeks); the use of lower doses might have provided a better therapeutic outcome over an extended period of time through the aforementioned mechanisms 7 . Moreover, emerging preclinical evidence suggests an upregulation of counter-regulatory pathways in response to vanucizumab treatment. Specifically, dual antiangiogenic therapy with the anti-VEGF-ANG2 antibody A2V led to upregulation of PD-L1 on ECs and tumour cells in multiple mouse tumour models, resulting in suppression of anticancer immunity 16 . Of note, this immune-evasive mechanism could be counteracted by concomitant treatment with an anti-PD-1 antibody, resulting in improved tumour control 16 . The benefits of dual VEGF-ANG2 inhibition are likely to be tumour dependent. We hypothesize that dual VEGF-ANG2 blockade might be particularly effective against tumours of the CNS. Glioblastomas are particularly hypoxic, which poses a considerable challenge to therapy 7, 77 , and normalizing brain tumour blood vessels for an extended period of time might help overcome this obstacle. In addition, the high abundance of macrophages in glioblastomas 91 ICAM1, and VCAM1, expressed on the luminal surface of ECs lining blood vessels and must then cross the endothelial barriers. Dual anti-VEGF-ANG2 therapy with A2V has been shown to upregulate the expression of adhesion molecules during the window of vascular normalization and can thereby facilitate the accumulation of anticancer T cells within multiple types of tumours in mice 16 . This finding is in line with the results of earlier preclinical studies that demonstrated increased tumour infiltration by T cells in response to low doses of an anti-VEGFR2 antibody -during the window of normalization 27 . In these models, antiangiogenic treatment several days before immunotherapy, by either vaccination or adoptive cell transfer approaches, increased the accumulation of T cells within the tumour and thus increased anticancer efficacy compared with vaccination therapy alone 27, 96 . Anti-VEGF therapy is also known to induce DC maturation and thus inhibit the priming of T cells. Additionally, loss of VEGF in T cells results in vessel normalization and an improved chemotherapeutic response in mice 97 . Importantly, although loss of VEGF expression by T cells might potentiate anticancer responses through vascular normalization, this effect might be compromised by the decreased capacity of VEGF-deficient T cells to infiltrate tumours and thus control tumour growth 97 . Indeed, the aforementioned upregulation of PD-L1 expression on ECs, which renders PD-1-expressing CTLs dysfunctional, has been highlighted as a possible mechanism of could potentially render these tumours particularly sensitive to dual VEGF-ANG2 inhibition owing to the ability of these treatments to reprogramme macrophages towards an anticancer phenotype, as observed in preclinical models 35, 36 . Targeting nonredundant vessel normalization pathways by inhibiting the renin-angiotensin system is another way to potentially further extend the window of normalization 94, 95 . In line with this hypothesis, the results of a retrospective study demonstrated that patients with recurrent glioblastoma who were treated with bevacizumab and used angiotensin receptor blockers (ARBs) had prolonged overall survival compared with those who did not use ARBs (HR 0.65, 95% CI 0.46-0.92; P = 0.016), including the subgroup treated with low-dose bevacizumab (area under the curve for bevacizumab <3.6 mg/kg per week) 75 . In summary, the available clinical data underscore that the successful translation of dual anti-VEGF-ANG2 therapy will require careful mechanistic studies and biomarker-driven clinical trial designs.
Normalization improves immunotherapy
Immunotherapy has rapidly transformed the anticancer treatment and drug development landscape; however, many patients do not benefit from this approach. The success of immunotherapy relies on the recruitment, expansion, and effective anticancer activity of immune cells, especially CTLs, in the TME.
The accumulation of T cells occurs via a multistep process. First, T cells must interact with adhesion molecules, such as E-selectin,
Box 4 | VEGF and ANG2 as prognostic and/or predictive biomarkers
No validated predictive biomarkers of a response to therapy targeting the VEGF signalling pathway have been identified in patients with cancer 7, 77 . Angiopoietin 2 (ANG2) is one potential biomarker of resistance to VEGF-targeted therapy. The results of some clinical studies using the VEGFA-neutralizing antibody bevacizumab have shown increased levels of circulating ANG2 after treatment 165 , whereas others have shown that serum ANG2 levels remain stable throughout the course of bevacizumab treatment 166 . In patients with ovarian cancer, however, a decrease in circulating ANG2 levels in response to VEGF pathway inhibition with sunitinib is correlated with a trend towards longer progression-free survival 167 . Moreover, we demonstrated in patients with glioblastoma that treatment with the pan-VEGF receptor tyrosine kinase inhibitor cediranib transiently decreases levels of plasma ANG2 (REF. 67 ). Nevertheless, a paucity of data exists on the kinetics of circulating ANG2 levels and tumour ANG2 expression in response to anti-VEGF therapy.
ANG2 needs to be explored as a potential predictive and/or prognostic biomarker because high levels of ANG2 in the tumour or in the circulation are correlated with unfavourable patient survival across multiple cancer types, including glioblastoma 166 , neuroendocrine tumours 159 , ovarian cancer 160 , metastatic melanoma 161 , breast cancer 45 , hepatocellular carcinoma 168 , pancreatic ductal carcinoma 169 , and gastric carcinoma 170 (Supplementary Table S6 ). Moreover, high levels of circulating ANG2 are associated with unfavourable outcomes of bevacizumab-based therapy in colorectal carcinoma 171 . Notably, a study in patients with metastatic melanoma treated with immune-checkpoint inhibitors revealed that high levels of circulating ANG2 correlate with an unfavourable treatment response and prognosis, possibly reflecting hypoxia and immunosuppression in the tumour microenvironment 68 .
resistance to dual VEGF-ANG2 blockade 16 . Similarly, upregulation of PD-L1 has been demonstrated on both ECs and tumour cells following treatment with anti-VEGFR2 therapy 98 . Thus, a strong rationale supports the combination of antiangiogenic agents and therapies that improve the functions of T cells in tumours. In fact, the findings of multiple preclinical studies provide evidence of the efficacy of combining vascularnormalizing agents with interventions that alleviate functional blockade of T cells, such as immune-checkpoint inhibitors (TABLE 1) . For example, ICB with an anti-PD-1 antibody improved the degree of tumour control achieved with the anti-ANG2-VEGF antibody A2V in various cancer models 16 . The combination of anti-VEGFR2 and anti-PD-L1 antibodies, however, did not improve survival in a glioblastoma model 98 . This lack of efficacy was attributed to a low incidence of high endothelial venules (HEVs) within these tumours, contrary to findings in models of breast cancer and PNETs, in which this combination was efficacious. HEVs are specialized vascular units, usually organized as tertiary lymphoid structures, which facilitate the recruitment and extravasation of naive T cells, and then promote the differentiation of these cells into CTLs. The ECs lining HEVs are known to express ICAM1 and VCAM1, and thus facilitate homing and migration of immune cells to tumours 98 . These findings are of particular importance because anti-PD-1 treatment alone conferred a survival benefit for only a small fraction of patients with glioblastoma 99 and failed to improve the outcomes of patients with this disease in a randomized phase III trial 100 . Anti-PD-1 antibodies have also been shown to provide limited therapeutic benefit in a less immunogenic breast tumour model (MMTV-PyMT) 16 . Thus, treatments that can induce HEV formation and/or increase antigen load, which include radiation, chemotherapy, and cancer vaccines, might enhance the therapeutic benefits of ICB [101] [102] [103] [104] . Notably, HEV formation in the aforementioned breast cancer and PNET models was found to be mediated by lymphotoxin-β receptor (LTβR) signalling, and treatment with an agonistic anti-LTβR antibody induced HEVs in the previously recalcitrant glioblastoma model, increased CTL activity, and thereby increased the efficacy of combined anti-VEGFR2 and anti-PD-L1 therapy 98 . Interestingly, ICB of cytotoxic T lymphocyte protein 4 (CTLA-4) and PD-1 can normalize blood vessels in multiple models of transplanted breast and other tumours 105 . The vascular normalization effect observed in this study was attributed to increased CD4 + type 1 T helper (T H 1) cell accumulation and anticancer activity 105 . However, this evidence was derived using CD4 + T cell-deficient animals or anti-CD4 antibody treatment before breast tumour inoculation; thus, the roles of T reg cells versus those of other populations of CD4 + T cells could not be separated. Hence, the effects of T H 1 cells on vascular normalization in the context of ICB need to be further validated in other preclinical models and through comparisons of patient biopsy specimens obtained before and after ICB. Importantly, although the generalizability of the reciprocal regulation of tumour vessel normalization and immunostimulatory reprogramming is supported by analyses of large transcriptomic databases in human tumours, the experimental studies were limited to breast cancer models 105 . Whether ICB-mediated vessel normalization is induced across a range of tumour types remains to be determined. If found to be broadly applicable, this mechanism provides another rationale for the pursuit of combinatorial approaches using antiangiogenic agents and immunecheckpoint inhibitors, as these therapies target nonredundant pathways for vessel normalization and abrogation of immunosuppression in the TME.
Perspectives
Compelling preclinical and clinical evidence indicates that anti-VEGF therapy creates a transient window of vessel normalization during which the delivery of oxygen -a radiosensitizer and immuno stimulator -and various therapeutic agents to tumours is improved 7, 62 . The extent of normalization varies with tumour type, as well as with the duration of treatment and the dosage of drug, and closure of the normalization window is marked by the development of adaptive tumour resistance and immunosuppression 7 . Tumours might escape anti-VEGF therapies mainly through alternative modes of vascularization (such as vessel co-option) and/or upregulation of alternative angiogenic pathways (such as ANG2-TIE2 signalling). Thus, targeting both the VEGF and ANG2 pathways concomitantly increases the efficacy of antiangiogenic treatments beyond that of monotherapy targeting either of these cytokines in preclinical studies 35, 36 . The treatment benefits observed with antiangiogenic therapy in animal models stem, in part, from restoration of anticancer immunity in the TME 16 , and this mechanism has formed the basis for combining antiangiogenic therapies with various immunotherapies, including tumour vaccines, chimeric antigen receptor (CAR) T cells, and immune-checkpoint inhibitors (TABLE 1) . On the basis of positive preclinical data, these combinations are now being tested in multiple clinical trials, with promising outcomes reported for patients with RCC in a phase II trial 65 (TABLE 2) . However, these therapies have complex biological effects, and combining them is likely to further increase this complexity; an increased risk of toxicities, particularly immune-related adverse events such as autoimmune colitis 5 , might ensue. Here, we outline some of the challenges and opportunities that lie ahead, highlighting future research priorities.
The results of both preclinical and retrospective clinical studies have demonstrated that the dosage of agents targeting the VEGF pathway is a key consideration 6, 7 . Historically, the clinical development of these agents has been predicated on the use of maximum tolerated doses until disease progression. High doses and/or a prolonged duration of anti-VEGF treatment are correlated with lower levels of tumour perfusion and elevated hypoxia 27 . The addition of agents that target the ANG2-TIE2 pathway to VEGF pathway blockade seems to extend the window of vascular normalization and convert an immunosuppressive microenvironment into an immunostimulatory milieu 35, 36 ; however, over time, tumours again become hypoxic and escape from this combined treatment approach via upregulation of PD-L1 on tumour cells and stromal cells of the TME, including ECs and immune cells 98 . Thus, a critical need exists to optimize the dosage, duration, and sequence of administration of antiangiogenic agents for use in combination with ICB.
ICB can have vessel-normalizing effects in preclinical models of breast tumours 105 , although the kinetics of vascular normalization are unknown. Obtaining this knowledge would facilitate efforts to optimally sequence the administration of immune-checkpoint inhibitors and antiangiogenic agents, in order to extend the window of normalization and, thus, the survival benefits 106 .
Of note, ICB is known to increase the risk of oedema in patients with brain tumours, sometimes resulting in death 107, 108 . This observation contrasts with the vascular normalization induced by ICB in breast cancer models 105 and suggests that the vascular effects are dependent on the tumour location and/or type -a possibility that needs to be further investigated. Nevertheless, anti-VEGF agents can reduce glioblastoma-associated brain oedema in mice and patients 63, 109 , providing a strong rationale for combining low-dose anti-VEGF therapy with ICB and other forms of immunotherapy for this disease, and potentially also brain metastases.
ICBs are known to cause sometimes severe immune-related adverse events. These toxicities can often be resolved by discontinuing ICB therapy or reducing the doses of the immune-checkpoint inhibitors used 5 . Considering that vascular normalization can improve the delivery of therapeutic agents to tumours 7 , the proposed combination strategy might require lower doses of immune-checkpoint inhibitors to confer immunostimulation but also to reduce the risk of toxicity.
Neither anti-VEGF therapy nor ICB seem to be effective in highly desmoplastic tumours, such as pancreatic ductal adenocarcinoma, breast cancer, and cholangiocarcinoma 7, 110 -with the notable exception of desmoplastic melanomas, which have been shown to respond to ICB 111 . The reasons for this lack of responsiveness are currently unknown, although results from our laboratory have shown that the elevated levels of extracellular matrix molecules, including collagen I and hyaluronan, in such tumours can compress blood vessels, impairing their function and resulting in hypoxia 94 . We have also shown that widely prescribed ARBs can normalize the stroma and decompress blood vessels, thereby improving the outcome of chemotherapy 94 . Moreover, RNA sequencing analyses of tumour specimens from patients with pancreatic ductal adenocarcinoma have revealed that ARBs can activate both the innate and adaptive immune system 112 . Thus, the testing of combinations of ARBs with antiangiogenic agents 113 and immune-checkpoint inhibitors 95 is warranted.
Obesity is associated with an unfavourable prognosis across multiple types of cancer 114 . Notably, an increased severity of adverse effects has been observed in obese versus nonobese mice following immunotherapy 115 ; however, the mechanisms underlying this increase are not understood. Given that obesity is an emerging public health problem worldwide, this relationship demands urgent investigation with regard to combined antiangiogenesis and immunotherapies.
We have focused on VEGF and angiopoietins as key targets for achieving vascular normalization; however, the duration and extent of normalization that can be achieved by specifically targeting these pathways might be limited. Certain molecularly targeted agents, such as the anti-HER2 antibody trastuzumab, and metronomic chemotherapy can also induce vascular normalization via upregulation of thrombospondin expression 28, 116, 117 . Moreover, endocrine therapy for hormone-dependent tumours can also reduce VEGF levels and normalize tumour vessels 118 . Similarly, novel approved drugs, including poly [ADP-ribose] polymerase inhibitors and cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors, might potentiate the effectiveness of immunotherapies, in part, by vascular normalization 119 . Novel vascular normalization strategies targeting these additional pathways should be further explored.
In addition to ICB, other immunotherapy approaches are also showing promise for the treatment of solid tumours 120 . Thus, the concepts discussed herein might also be applicable to CAR T cells and immuno stimulatory or bi-functional antibodies in terms of improving their delivery and effectiveness.
A number of preclinical studies have demonstrated that cytotoxic therapies (radiation and chemotherapy) can be used to increase the neoantigen load of tumours that have a low baseline neoantigen load, which is a barrier to effective immunotherapy 121 . Again, by increasing the functionality of tumour vessels and fostering an immuno supportive TME (FIG. 4) , vascular normalization approaches might not only improve the development of anticancer immunity, but also decrease the required doses of cytotoxic therapies and thus reduce the adverse effects of combinations incorporating immunotherapies.
The microbiota is emerging as a determinant of responses to various anticancer therapies, including immunotherapy [122] [123] [124] [125] . Virtually nothing is known, however, about the role of the microbiome in antiangiogenic therapy and vice versa. Thus, exploring the interactions among the microbiota, immunotherapy, and antiangiogenic therapy might offer exciting opportunities to improve the survival of patients with cancer.
Finally, no validated biomarkers are available to guide the use of antiangiogenic drugs 7, 126 . Similarly, biomarkers to evaluate responses to ICB, beyond MSI-H, dMMR, and PD-L1 positivity (which have suboptimal predictive utility), are urgently needed 5 .
Optimally combining antiangiogenic therapy with ICB would require a concerted effort in this area owing to the costs and adverse effects of these treatments, which necessitate efforts to limit their use to patients who will derive clinical benefit.
Conclusions
In summary, immune-checkpoint inhibitors and antiangiogenic drugs are widely and increasingly prescribed, and are under continued developed in clinical trials, for the treatment of a range of solid tumours (Supplementary Table S1 and Supplementary  Table S2 ). ICB can dramatically prolong the survival of patients who have durable responses, but has generally failed to improve the outcomes of the remaining majority of patients, at the cost of substantial toxicities in many recipients. Antiangiogenic drugs offer only a modest survival benefit of a few weeks to months, with rare durable responses. Herein, we have discussed the potential to rationally combine these two approaches in order to increase patient survival beyond that currently conferred by each approach individually. Despite the outstanding challenges, including the currently high costs and considerable risks of adverse effects associated with these treatment modalities, compelling evidence supports the combination of antiangiogenic and ICB therapies. The evidence indicates that the potential benefit of such combinations will be manifested though modulation of both the tumour vasculature and the tumour immune microenvironment. We await, with interest, the outcomes of ongoing clinical trials that are investigating whether the combination of antiangiogenic therapy with ICB will realize the full potential of this approach to improve the survival of patients with cancer. We also anticipate that the development of predictive biomarkers and orally available inhibitors of immune checkpoints, as well as competition among the companies manufacturing these agents, will help bring down the costs associated with these treatments in the future.
